Get the Stockscreener App
1.54
0.65%
0.01
After Hours:
1.51
-0.03
-1.95%
Lava Therapeutics Nv stock is traded at $1.54, with a volume of 104.96K.
It is up +0.65% in the last 24 hours and up +4.05% over the past month.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
See More
Previous Close:
$1.53
Open:
$1.52
24h Volume:
104.96K
Relative Volume:
1.53
Market Cap:
$40.51M
Revenue:
$9.06M
Net Income/Loss:
$-50.39M
P/E Ratio:
-0.8021
EPS:
-1.92
Net Cash Flow:
$5.89M
1W Performance:
+0.65%
1M Performance:
+4.05%
6M Performance:
+63.85%
1Y Performance:
-12.99%
1-Day Range:
$1.52
$1.56
1-Week Range:
$1.51
$1.56
52-Week Range:
$0.8502
$2.093
Lava Therapeutics Nv Stock (LVTX) Company Profile
Name
Lava Therapeutics Nv
Sector
Industry
Phone
31 6 3000 3035
Address
YALELAAN 62, UTRECHT
Compare LVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LVTX
Lava Therapeutics Nv
|
1.54 | 40.25M | 9.06M | -50.39M | 5.89M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.30 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.97 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.73 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
652.43 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.69 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Lava Therapeutics Nv Stock (LVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-11-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-25-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-21 | Initiated | JP Morgan | Overweight |
| Apr-19-21 | Initiated | Jefferies | Buy |
| Apr-19-21 | Initiated | SVB Leerink | Outperform |
View All
Lava Therapeutics Nv Stock (LVTX) Latest News
LAVA Therapeutics Announces Acquisition by XOMA Corporation - TipRanks
Is LAVA Therapeutics N.V. forming a bottoming baseJuly 2025 Movers & Low Drawdown Momentum Ideas - Newser
Signal strength of LAVA Therapeutics N.V. stock in tech scannersShort Setup & Real-Time Volume Triggers - Newser
Automated trading signals detected on LAVA Therapeutics N.V.Volume Spike & Daily Market Momentum Tracking - Newser
What earnings revisions data tells us about LAVA Therapeutics N.V.Trend Reversal & Stepwise Swing Trade Plans - Newser
LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Press Release: LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update - 富途牛牛
Published on: 2025-08-13 07:23:25 - Newser
Published on: 2025-08-13 04:30:20 - Newser
Real time scanner hits for LAVA Therapeutics N.V. explainedMarket Volume Report & Free Community Consensus Stock Picks - Newser
Real time breakdown of LAVA Therapeutics N.V. stock performanceJuly 2025 Market Mood & High Yield Equity Trading Tips - Newser
Is a relief rally coming for LAVA Therapeutics N.V. holdersBuy Point Strategy with Profit Protection - Newser
Has LAVA Therapeutics N.V. formed a bullish divergence2025 Institutional Moves & Long Hold Capital Preservation Plans - Newser
LAVA Therapeutics N.V. stock momentum explainedDay Trading Plan with Entry Risk Management - Newser
Lava Therapeutics shares rise 1.32% intraday after XOMA Royalty Corporation's acquisition of Turnstone Biologics Corp. - AInvest
Is it too late to sell LAVA Therapeutics N.V.Free Beginner Friendly Stock Selection Guide - Newser
What makes LAVA Therapeutics N.V. stock price move sharplyTrade Plan With Low Risk High Return - Newser
Tools to assess LAVA Therapeutics N.V.’s risk profileImmediate Entry Point Prediction Strategy - Newser
Is LAVA Therapeutics N.V. stock poised for growthFree Multi-Bagger Potential Stock Forecast Tools - Newser
How LAVA Therapeutics N.V. stock performs during market volatilityPattern Breakout Tracker with Screener Tools - Newser
LAVA Therapeutics N.V.’s Price Action Aligns with Quant SignalsWeekly Return Pick Forecast Reports Show Trend - beatles.ru
Can a trend reversal in LAVA Therapeutics N.V. lead to recoveryFree Risk-Adjusted Picks With Exit Strategy - Newser
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of LAVA Therapeutics N.V. (NASDAQ: LVTX) - Eastern Progress
XOMA Royalty Announces Dual Acquisitions of HilleVax and LAVA Therapeutics - MSN
Will breakout in LAVA Therapeutics N.V. lead to full recoveryRisk Managed Watchlist with Breakout Picks - Newser
Lava Therapeutics shares rise 1.18% intraday after XOMA Royalty Corporation acquisition announcement. - AInvest
LAVA Therapeutics (NASDAQ:LVTX) Cut to “Hold” at Jefferies Financial Group - Defense World
Investigation into Steelcase, LAVA Therapeutics, and Enzo Biochem on Behalf of Shareholders - AInvest
Live market analysis of LAVA Therapeutics N.V.Stock Forecast Tools for Retail Traders - Newser
East Bay’s Xoma adds two more biotechs to its portfolio - The Business Journals
Lava Therapeutics Nv Stock (LVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
1.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):